The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The findings revealed that an overwhelming 84% of patients with Parkinson’s disease report struggling with sleep issues—significantly higher than the general population of the same age group. The ...

Caffeine Affects Brain Dopamine Function in Patients With Parkinson's Disease May 28, 2024 — Regular high caffeine consumption affects dopamine function in patients with Parkinson's disease ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

A man fitted with a pioneering, computer-controlled brain implant to tackle his Parkinson's disease says it ... on the quality of life of patients with the disease. He began getting symptoms ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

A Colorado Springs family hopes to win what they believe would be a landmark legal verdict by proving to jurors next month ...

A new EPA ban on TCE, a common industrial cleaning agent and contaminant, begins this year. UCSF’s Samuel Goldman, who led groundbreaking research to link TCE to Parkinson’s Disease, talks about the ...

DelveInsight's Parkinson's disease Psychosis market Report provides comprehensive insights into the epidemiology and market dynamics across the 7MM. LAS VEGAS , NV, UNITED STATES, January 30, 2025 ...